Dr. Franziska Münz | Medicine and Dentistry | Future Science Leader Award
100
75
50
25
0
97
10
5
100
75
50
25
0
Professor at Yonsei University College of Medicine | South Korea
Dr. Taeyoung Kyong is a medical academic and clinician recognized for expertise in hospital medicine and inpatient care. His education and professional training underpin a strong foundation in internal medicine and clinical research. He has extensive experience integrating patient-centered practice with system-based healthcare improvement. His research interests focus on hospitalist-led care models, diabetes management, quality improvement, and digital health applications. Overall, Dr. Taeyoung Kyong’s work reflects a sustained commitment to advancing evidence-based inpatient medicine and healthcare excellence.
Professor at Klinikum Hanau | Germany
Medical Oncologist at Hospital 12 de Octubre | Spain
Baena Espinar, J. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab outside clinical trials: Pembro-real 5Y registry results. Journal for Immunotherapy of Cancer.
Baena Espinar, J., et al. (2025). Clinical utility of combined tissue and plasma next-generation sequencing in treatment-naïve advanced NSCLC. JTO Clinical and Research Reports.
Baena Espinar, J., et al. (2025). Efficacy and safety of lorlatinib in ALK- and ROS1-rearranged metastatic NSCLC within the compassionate use program in Spain.
Baena Espinar, J., et al. (2025). Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in lung cancer patients.
Baena Espinar, J., et al. (2025). Safety and efficacy of immune checkpoint therapy in patients with cardiac metastasis: A multicenter international retrospective analysis.
Baena Espinar, J., et al. (2025). Unmet needs in maintenance therapy for extensive-stage small cell lung cancer.
Baena Espinar, J. (2024). Consolidation osimertinib vs durvalumab vs observation after chemoradiation in unresectable EGFR-mutant NSCLC. Journal of Thoracic Oncology.
Baena Espinar, J.(2024). Facts and hopes on cancer immunotherapy for small cell lung cancer. Clinical Cancer Research.
Baena Espinar, J.(2024). Real-world data of first-line cemiplimab monotherapy for PD-L1 high NSCLC. Journal of Thoracic Oncology.
Baena Espinar, J.(2024). Multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage SCLC. Clinical Cancer Research.
Baena Espinar, J.(2024). Targeting KRAS G12C in NSCLC: Current standards and developments. Drugs.
Baena Espinar, J.(2023). Future perspectives in second-line therapy for non-oncogene–addicted NSCLC. Cancers.
Baena Espinar, J. (2023). Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer. Journal of Clinical Oncology.
Baena Espinar, J.(2022). Updated prognostication system for thoracic malignancies with COVID-19: TERAVOLT registry. Journal of Thoracic Oncology.
Baena Espinar, J. (2022). COVID-19 outcomes, vaccination status, and cancer-related delays during the Omicron wave: TERAVOLT analysis. JTO Clinical and Research Reports.
Oh, C. K., Ariue, B., Alban, R. F., Shaw, B., & Cho, S. H. (2002). PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochemical and Biophysical Research Communications, 294(5), 1155–1160.
Heimall, J., Keller, M., Saltzman, R., Bunin, N., McDonald-McGinn, D., Ariue, B., … Markert, M. L. (2012). Diagnosis of 22q11.2 deletion syndrome and Artemis deficiency in two children with T-B-NK+ immunodeficiency. Journal of Clinical Immunology, 32(5), 1141–1144.
Cho, S. H., Hall, I. P., Wheatley, A., Ariue, B. K., Abraha, D., Delmundo, J., & Oh, C. K. (2001). The possible role of plasminogen activator inhibitor-1 gene in the development of asthma. Journal of Allergy and Clinical Immunology, 107.
Ariue, B. K., Cho, S. H., Tam, S. W., & Oh, C. K. (2001). 142 Analysis of airway remodeling genes in human mast cells by cDNA microarrays. Journal of Allergy and Clinical Immunology, 107.
Ariue, B. K. & Oh, C. K. (2005). Chapter 43 – Anaphylaxis (in book chapter). In Pediatrics. Mosby Inc.
Ariue, B. K. & Oh, C. K. (2005). Chapter 48 – Insect allergies (in book chapter). In Pediatrics. Mosby Inc.
McDonnell, J., Angarola, B., Ariue, B., Arnold, D. E., Assa’ad, A. H., Aytekin, C., … Bleesing, J. (2024). COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs: a USIDNET report. Journal of Clinical Immunology.
Professor at Link Campus University | Italy
Prof. Luca Roncati is an accomplished Italian physician-scientist, pathologist, and academic who has made outstanding contributions to medicine and dentistry through his pioneering research, teaching, and clinical leadership. He earned his Ph.D. in Pathology, building a solid academic foundation that has enabled him to excel in translational research across multiple domains including senology, gynecologic oncology, gynecopathology, and hematopathology. Currently, he serves as a Full Professor of Pathology at Link Campus University in Rome and as Head of the Women’s Health Department at the European Institute of Dermatology in Milan, where he integrates patient care with innovative research. His professional experience also extends to forensic pathology and editorial responsibilities, highlighting his multidisciplinary expertise and leadership in the scientific community. Prof. Luca Roncati’s research interests span cancer biology, nanopathology, women’s health, and infectious diseases, with significant contributions to the understanding of COVID-19 pathology, exemplified by several highly cited publications. His skills include advanced diagnostic pathology, molecular biology, nanotechnology applications in medicine, and academic mentorship, as well as the ability to translate complex findings into practical healthcare solutions. With over 227 publications, 1,726 citations by 1,064 documents, and an h-index of 23, his academic output reflects sustained global impact and recognition. His innovative work includes the description of the Roncati-Manenti triad and T rex lymphoma, and his authorship of more than 280 peer-reviewed publications in high-impact journals has positioned him as a global thought leader. Prof. Luca Roncati has received numerous honors as an award-winning author and inventor of anti-cancer patents, underscoring his capacity to merge science with innovation. In conclusion, Prof. Luca Roncati’s distinguished academic record, clinical leadership, and groundbreaking contributions to oncology, nanopathology, and women’s health make him a leading figure in medicine whose continued work promises to advance medical research, patient care, and global health standards.
Profile: Scopus
Roncati, L. (2020). The COVID-19 syndrome: a clinical perspective. Clinical Immunology, 215, 108487.
Roncati, L. (2020). Endothelial–platelet interactions in COVID-19. Annals of Hematology, 99(9), 1955–1956.
Roncati, L. (2020). T rex lymphoma: a novel hematologic entity. Current Medical Research and Opinion, 36(3), 511–514.
Roncati, L. (2017). Nanopathology: the health impact of nanoparticles. Nanotoxicology, 11(7), 884–888.
Roncati, L. (2016). The Roncati–Manenti triad in gynecologic oncology. International Journal of Gynecological Cancer, 26(8), 1584–1585.
Roncati, L. (2019). The forensic challenges in the study of nanoparticle exposure. Forensic Science International, 301, 309–315.
Roncati, L. (2018). Molecular pathology insights into breast cancer. Pathology Research and Practice, 214(12), 2000–2005.